FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2340968189> ?p ?o ?g. }

• W2340968189 endingPage "2027" @default.
• W2340968189 startingPage "2020" @default.
• W2340968189 abstract "Four US National Clinical Trials Network components (Southwest Oncology Group, Cancer and Leukemia Group B/Alliance, Eastern Cooperative Oncology Group, and the AIDS Malignancy Consortium) conducted a phase II Intergroup clinical trial that used early interim fluorodeoxyglucose positron emission tomography (FDG-PET) imaging to determine the utility of response-adapted therapy for stage III to IV classic Hodgkin lymphoma.The Southwest Oncology Group S0816 (Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma) trial enrolled 358 HIV-negative patients between July 1, 2009, and December 2, 2012. A PET scan was performed after two initial cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and was labeled PET2. PET2-negative patients (Deauville score 1 to 3) received an additional four cycles of ABVD, whereas PET2-positive patients (Deauville score 4 to 5) were switched to escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) for six cycles. Among 336 eligible and evaluable patients, the median age was 32 years (range, 18 to 60 years), with 52% stage III, 48% stage IV, 49% International Prognostic Score 0 to 2, and 51% score 3 to 7.Three hundred thirty-six of the enrolled patients were evaluable. Central review of the interim PET2 scan was performed in 331 evaluable patients, with 271 (82%) PET2-negative and 60 (18%) PET2-positive. Of 60 eligible PET2-positive patients, 49 switched to eBEACOPP as planned and 11 declined. With a median follow-up of 39.7 months, the Kaplan-Meier estimate for 2-year overall survival was 98% (95% CI, 95% to 99%), and the 2-year estimate for progression-free survival (PFS) was 79% (95% CI, 74% to 83%). The 2-year estimate for PFS in the subset of patients who were PET2-positive after two cycles of ABVD was 64% (95% CI, 50% to 75%). Both nonhematologic and hematologic toxicities were greater in the eBEACOPP arm than in the continued ABVD arm.Response-adapted therapy based on interim PET imaging after two cycles of ABVD seems promising with a 2-year PFS of 64% for PET2-positive patients, which is much higher than the expected 2-year PFS of 15% to 30%." @default.
• W2340968189 created "2016-06-24" @default.
• W2340968189 creator A5001102192 @default.
• W2340968189 creator A5005273991 @default.
• W2340968189 creator A5005446802 @default.
• W2340968189 creator A5006117950 @default.
• W2340968189 creator A5009574158 @default.
• W2340968189 creator A5014543424 @default.
• W2340968189 creator A5014743270 @default.
• W2340968189 creator A5015672299 @default.
• W2340968189 creator A5016175407 @default.
• W2340968189 creator A5027080346 @default.
• W2340968189 creator A5031758990 @default.
• W2340968189 creator A5037882455 @default.
• W2340968189 creator A5038526399 @default.
• W2340968189 creator A5041539801 @default.
• W2340968189 creator A5041588764 @default.
• W2340968189 creator A5055100327 @default.
• W2340968189 creator A5064091455 @default.
• W2340968189 creator A5066731616 @default.
• W2340968189 creator A5069054551 @default.
• W2340968189 creator A5072154632 @default.
• W2340968189 creator A5078791373 @default.
• W2340968189 creator A5082606841 @default.
• W2340968189 creator A5083914569 @default.
• W2340968189 creator A5085712310 @default.
• W2340968189 creator A5085801543 @default.
• W2340968189 date "2016-06-10" @default.
• W2340968189 modified "2023-10-17" @default.
• W2340968189 title "US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose–Positron Emission Tomography Imaging: Southwest Oncology Group S0816" @default.
• W2340968189 cites W1541614540 @default.
• W2340968189 cites W1874071964 @default.
• W2340968189 cites W2001261680 @default.
• W2340968189 cites W2010746974 @default.
• W2340968189 cites W2014663568 @default.
• W2340968189 cites W2034400622 @default.
• W2340968189 cites W2039888190 @default.
• W2340968189 cites W2047185642 @default.
• W2340968189 cites W2050942542 @default.
• W2340968189 cites W2076334524 @default.
• W2340968189 cites W2080726207 @default.
• W2340968189 cites W2101873015 @default.
• W2340968189 cites W2119147717 @default.
• W2340968189 cites W2119843363 @default.
• W2340968189 cites W2123957608 @default.
• W2340968189 cites W2131900456 @default.
• W2340968189 cites W2133201432 @default.
• W2340968189 cites W2133260927 @default.
• W2340968189 cites W2136652821 @default.
• W2340968189 cites W2136962826 @default.
• W2340968189 cites W2137965731 @default.
• W2340968189 cites W2150456018 @default.
• W2340968189 cites W2164900174 @default.
• W2340968189 cites W2328676772 @default.
• W2340968189 cites W2598700764 @default.
• W2340968189 cites W4293241248 @default.
• W2340968189 doi "https://doi.org/10.1200/jco.2015.63.1119" @default.
• W2340968189 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4966513" @default.
• W2340968189 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27069074" @default.
• W2340968189 hasPublicationYear "2016" @default.
• W2340968189 type Work @default.
• W2340968189 sameAs 2340968189 @default.
• W2340968189 citedByCount "210" @default.
• W2340968189 countsByYear W23409681892016 @default.
• W2340968189 countsByYear W23409681892017 @default.
• W2340968189 countsByYear W23409681892018 @default.
• W2340968189 countsByYear W23409681892019 @default.
• W2340968189 countsByYear W23409681892020 @default.
• W2340968189 countsByYear W23409681892021 @default.
• W2340968189 countsByYear W23409681892022 @default.
• W2340968189 countsByYear W23409681892023 @default.
• W2340968189 crossrefType "journal-article" @default.
• W2340968189 hasAuthorship W2340968189A5001102192 @default.
• W2340968189 hasAuthorship W2340968189A5005273991 @default.
• W2340968189 hasAuthorship W2340968189A5005446802 @default.
• W2340968189 hasAuthorship W2340968189A5006117950 @default.
• W2340968189 hasAuthorship W2340968189A5009574158 @default.
• W2340968189 hasAuthorship W2340968189A5014543424 @default.
• W2340968189 hasAuthorship W2340968189A5014743270 @default.
• W2340968189 hasAuthorship W2340968189A5015672299 @default.
• W2340968189 hasAuthorship W2340968189A5016175407 @default.
• W2340968189 hasAuthorship W2340968189A5027080346 @default.
• W2340968189 hasAuthorship W2340968189A5031758990 @default.
• W2340968189 hasAuthorship W2340968189A5037882455 @default.
• W2340968189 hasAuthorship W2340968189A5038526399 @default.
• W2340968189 hasAuthorship W2340968189A5041539801 @default.
• W2340968189 hasAuthorship W2340968189A5041588764 @default.
• W2340968189 hasAuthorship W2340968189A5055100327 @default.
• W2340968189 hasAuthorship W2340968189A5064091455 @default.
• W2340968189 hasAuthorship W2340968189A5066731616 @default.
• W2340968189 hasAuthorship W2340968189A5069054551 @default.
• W2340968189 hasAuthorship W2340968189A5072154632 @default.
• W2340968189 hasAuthorship W2340968189A5078791373 @default.
• W2340968189 hasAuthorship W2340968189A5082606841 @default.
• W2340968189 hasAuthorship W2340968189A5083914569 @default.
• W2340968189 hasAuthorship W2340968189A5085712310 @default.
• W2340968189 hasAuthorship W2340968189A5085801543 @default.
• W2340968189 hasBestOaLocation W23409681892 @default.

• next